ATCC and the Broad Institute reported engineered isogenic cancer models intended to accelerate study of resistance to targeted therapies. The initial platform focuses on osimertinib-resistant non-small cell lung cancer models, built with CRISPR gene editing and gene overexpression to recreate resistance mechanisms observed in patients. The teams said the lab-made panel will allow direct comparisons of drug-sensitive and drug-resistant cells side by side, reducing the time required to develop models when patient tumor samples are scarce. Led by Broad cancer program director William R. Sellers and ATCC’s Fang Tian, the collaboration aims to produce both models and supporting datasets for the wider research community. ATCC’s Roth Cheng highlighted the goal of revealing additional targets and combination strategies that can turn treatment failures into new therapeutic opportunities.